Roxatidine

Drugbox|
IUPAC_name = 3- [3-(1-piperidylmethyl)phenoxy] propylcarbamoylmethyl acetate

---

width = 250
CAS_number=78628-28-1
ATC_prefix=A02
ATC_suffix=BA06
ATC_supplemental=
PubChem=5105
DrugBank=
C = 19 | H = 28 | N = 2 | O = 4
molecular_weight = 348.437 g/mol
bioavailability= 80–90%
protein_bound = 5–7%
metabolism = Hepatic deacetylation
Minor involvement of CYP2D6 and CYP2A6
elimination_half-life= 5–7 hours
excretion = Renal
pregnancy_category =
legal_status =
routes_of_administration= Oral

Roxatidine acetate is a specific and competitive H₂ receptor antagonist. The antisecretory effect of roxatidine acetate is mediated by its main metabolite, roxatidine.
Pharmacodynamic studies revealed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.

Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver.

It is currently sold in South Africa under the tradename Roxit.